Quick Answer
Eton Pharmaceuticals, Inc. reported Total Revenue of $79.95 million for the year ending 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +104.9% in Total Revenue from 2024 to 2025.
- This data is from Eton Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $500.0 thousand | Q4 2019: $459.0 thousand | Q1 2020: $99.0 thousand | Q2 2020: $20.0 thousand | Q3 2020: -$161.0 thousand | Q1 2021: $11.90 million | Q2 2021: $3.07 million | Q3 2021: $775.0 thousand | Q1 2022: $2.18 million | Q2 2022: $7.36 million | Q3 2022: $3.22 million | Q1 2023: $5.30 million | Q2 2023: $12.00 million | Q3 2023: $7.03 million | Q1 2024: $7.97 million | Q2 2024: $9.07 million | Q3 2024: $10.32 million | Q1 2025: $17.28 million | Q2 2025: $18.93 million | Q3 2025: $22.46 million.
- Over the full 7 years of available data (2019 to 2025), Eton Pharmaceuticals, Inc.'s Total Revenue has grown by 8,236.8%.
- Historical annual values: Fiscal year 2025: $79.95 million | Fiscal year 2024: $39.01 million | Fiscal year 2023: $31.64 million | Fiscal year 2022: $21.25 million | Fiscal year 2021: $21.83 million | Fiscal year 2020: $39.0 thousand | Fiscal year 2019: $959.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: